cas 1192813-64-1|| where to buy 2-Chloro-5-(difluoromethoxy)pyrimidine

Nombre del producto:2-Chloro-5-(difluoromethoxy)pyrimidine

IUPAC Name:2-chloro-5-(difluoromethoxy)pyrimidine

Unidad de embalaje	Stock disponible	Precio($)
CM325391-1g	in stock	ǶƎƦ
CM325391-5g	in stock	ưŵƦ
CM325391-10g	in stock	Ƕŵǜŵ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1192813-64-1 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1192813-64-1; Fórmula molecular:C5H3ClF2N2O; Punto de fusión:-; Código de sonrisas:FC(F)OC1=CN=C(Cl)N=C1; Densidad:

: Número de catálogo:CM325391; Peso molecular:180.54; Punto de ebullición:260.1±30.0°C at 760 mmHg; Nº Mdl:MFCD18415615; Almacenamiento:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: AZD0780; AstraZeneca announced Phase I trial data for its PCSK9 inhibitor, AZD0780. AZD0780 is an oral small molecule PCSK9 inhibitor as a first-in-class therapy for patients with dyslipidemia that cannot be controlled by statins alone. PSCK9 is a well-known and validated target in lipid metabolism and inhibiting PSCK9 signalling has shown to be effective in reducing LDL cholesterol levels in plasma. Lower LDL-C levels are associated with a reduction in the risk of long-term cardiovascular disease and major cardiovascular events.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.